Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients

Hypomethylating agents (HMA) are currently the only FDA approved therapy for patients with chronic myelomonocytic leukemia (CMML). In the current retrospective study, we assessed response rates as adjudicated by the IWG (International Working Group) MDS (myelodysplastic syndrome) and MDS/MPN myelopr...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2019-07, Vol.94 (7), p.767-779
Main Authors: Coston, Tucker, Pophali, Prateek, Vallapureddy, Rangit, Lasho, Terra L., Finke, Christy M., Ketterling, Rhett P., Carr, Ryan, Binder, Moritz, Mangaonkar, Abhishek A., Gangat, Naseema, Al‐Kali, Aref, Litzow, Mark, Zblewski, Darci, Pardanani, Animesh, Tefferi, Ayalew, Patnaik, Mrinal M.
Format: Article
Language:English
Subjects:
5-aza-2'-deoxycytidine
Acute myeloid leukemia
Adolescent
Adult
Aged
Aged, 80 and over
Azacitidine - administration & dosage
Chronic myelomonocytic leukemia
Decitabine - administration & dosage
Disease-Free Survival
Female
Genetic transformation
Hematology
Humans
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Male
Middle Aged
Myelodysplastic syndrome
Myelomonocytic leukemia
Remission
Response rates
Survival Rate
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypomethylating agents (HMA) are currently the only FDA approved therapy for patients with chronic myelomonocytic leukemia (CMML). In the current retrospective study, we assessed response rates as adjudicated by the IWG (International Working Group) MDS (myelodysplastic syndrome) and MDS/MPN myeloproliferative neoplasm overlap syndrome response criteria, in 121 CMML patients treated with Azacitidine (AZA, n = 56) and Decitabine (DAC, n = 65). The overall response rates were 41% by the IWG MDS (AZA‐ 45%, DAC‐39%), and 56% by the IWG MDS/MPN (AZA‐56%, DAC‐58%) response criteria, with CR (complete remission) rates of
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.25488